Home/Investors/Redmile Group

Redmile Group

Biotech Investor · 3 portfolio companies

Portfolio

3

Combined Value

$1.2B

Focus Areas

12

Top Stage

Phase 2

Investment Focus

Neuropsychiatry Neurology Autism Spectrum Disorder Schizophrenia Depression Alzheimer's Disease Rare Diseases Muscular Dystrophy Genetic Disorders Hematology Oncology Infectious Disease

Portfolio Companies

Company	Stage	Valuation	Focus
MapLight Therapeutics	Phase 2	$796.8M	Neuropsychiatry, Neurology
Fulcrum Therapeutics	Phase 3	$450.9M	Rare Diseases, Muscular Dystrophy
Clear Labs	Commercial	—	Oncology, Infectious Disease

Frequent Co-Investors

Public market investors1 shared Arch Venture Partners1 shared Venrock1 shared Fidelity Management & Research Company1 shared Kleiner Perkins1 shared Fidelity Investments1 shared Boxer Capital1 shared Entities associated with RA Capital1 shared